 
        
        
        TC-E 5003是一种选择性 PRMT1 抑制剂,对 hPRMT1 的 IC50 为 1.5 µM,还可调节 AP-1 和 NF-κB 信号通路,并具有抗炎特性。
 
                                 
                                
                            

| 规格 | 价格 | 会员价 | 库存 | 数量 | |||
|---|---|---|---|---|---|---|---|
| {[ item.pr_size ]} | {[ getRatePriceInt(item.pr_rmb, 1,1) ]}{[ getRatePriceInt(item.pr_rmb_sale, 1,1) ]} {[ suihuo_tips(item.pr_tag_price, item.pr_am) ]} | {[ getRatePriceInt(item.pr_rmb, 1,1) ]}{[ getRatePriceInt(item.pr_rmb,item.pr_rate,1) ]} {[ suihuo_tips(item.pr_tag_price, item.pr_am) ]} | {[ getRatePriceInt(item.pr_rmb, 1,1) ]}{[ suihuo_tips(item.pr_tag_price, item.pr_am) ]} | {[ getRatePrice(item.pr_rmb_sale, 1,1,item.mem_isinteger) ]} {[ getRatePrice(item.pr_rmb,item.pr_rate,item.mem_rate,item.mem_isinteger) ]} {[ getRatePrice(item.pr_rmb,1,item.mem_rate,item.mem_isinteger) ]} | 现货 | 1周 咨询 | - + | 
快速发货 顺丰冷链运输,1-2 天到达
品质保证
技术支持
免费溶解
 
                        
                    
| 描述 | Protein arginine methyltransferase 1 (PRMT1) is a major type 1 arginine methyltransferase associated with the activation of estrogen and androgen receptors; therefore, may represent a therapeutic target for hormone-dependent cancers. TC-E 5003 is an inhibitor of PRMT1 with an IC50 value of 1.5±0.2µM. The GI50 value of TC-E 5003 for the growth of MCF7a and LNCaP cell lines are 1.97 ± 0.14 and 4.49 ± 0.14µM, respectively.[1] TC-E 5003 at concentrations of 0.125 – 1µM dose-dependently suppressed lipopolysaccharide-induced nitric oxide (NO) production in RAW264.7 cells. Treatment with TC-E 5003 also markedly reduced the expressions of inducible NO synthase, cyclooxygenase-2, tumor necrosis factor-α, interleukin (IL)-1β, and IL-6, and downregulated the nuclear translocation of nuclear factor kappa B subunits.[2] TC-E-5003 at a dose of 0.5mg exerted an anti-tumor effect (31.76%) in A549 tumor-bearing mice.[3] | 
| 作用机制 | TC-E 5003 is a selective inhibitor of PRMT1.[1] | 
| Concentration | Treated Time | Description | References | |
| RAW264.7 cells | 0-1 µM | 15 min | TC-E inhibited c-Jun transcription in RAW264.7 cells after LPS treatment | Int J Mol Sci. 2020 Apr 26;21(9):3058. | 
| RAW264.7 cells | 0-1 µM | 15-30 min | TC-E decreased p-c-Jun levels but did not affect phosphorylated MAPKs | Int J Mol Sci. 2020 Apr 26;21(9):3058. | 
| RAW264.7 cells | 0-1 µM | 15-60 min | TC-E suppressed the nuclear translocation of NF-κB subunits p65 and p50 and AP-1 transcriptional factor c-Jun | Int J Mol Sci. 2020 Apr 26;21(9):3058. | 
| HEK293T cells | 0-1 µM | 24 hours | TC-E did not alter Src phosphorylation in Src-overexpressing HEK293T cells | Int J Mol Sci. 2020 Apr 26;21(9):3058. | 
| RAW264.7 cells | 0-1 µM | 24 hours | TC-E significantly reduced LPS-induced NO production without cytotoxicity | Int J Mol Sci. 2020 Apr 26;21(9):3058. | 
| RAW264.7 cells | 0-1 µM | 2-5 min | TC-E inhibited Src phosphorylation after 2 min of LPS treatment but not Syk | Int J Mol Sci. 2020 Apr 26;21(9):3058. | 
| MDA-MB-231 | 0.5965 µM (IC50) | 48 hours | Evaluate the anti-tumor effect of TC-E-5003 on MDA-MB-231 cells, IC50 was 0.5965 μM. | Drug Deliv. 2020 Dec;27(1):491-501. | 
| MCF-7 | 0.4128 µM (IC50) | 48 hours | Evaluate the anti-tumor effect of TC-E-5003 on MCF-7 cells, IC50 was 0.4128 μM. | Drug Deliv. 2020 Dec;27(1):491-501. | 
| NCL-H1299 | 0.6844 µM (IC50) | 48 hours | Evaluate the anti-tumor effect of TC-E-5003 on NCL-H1299 cells, IC50 was 0.6844 μM. | Drug Deliv. 2020 Dec;27(1):491-501. | 
| A549 | 0.7022 µM (IC50) | 48 hours | Evaluate the anti-tumor effect of TC-E-5003 on A549 cells, IC50 was 0.7022 μM. | Drug Deliv. 2020 Dec;27(1):491-501. | 
| RAW264.7 cells | 0-1 µM | 5 min | TC-E significantly downregulated IκBα phosphorylation after 5 min of LPS treatment | Int J Mol Sci. 2020 Apr 26;21(9):3058. | 
| RAW264.7 cells | 0-1 µM | 6 hours | TC-E downregulated the expression of inflammatory genes (iNOS, COX-2, TNF-α, IL-6) | Int J Mol Sci. 2020 Apr 26;21(9):3058. | 
| Administration | Dosage | Frequency | Description | References | ||
| ICR mice | A549 cell xenograft model | Subcutaneous injection | 0.5 mg | Single dose, lasting 28 days | Evaluate the anti-tumor effect of TC-E-5003-INEI in A549 xenograft model, tumor inhibition efficiency was 68.23%. | Drug Deliv. 2020 Dec;27(1):491-501. | 
| 计算器 | ||||
| 存储液制备 |  | 1mg | 5mg | 10mg | 
| 1 mM 5 mM 10 mM | 2.49mL 0.50mL 0.25mL | 12.46mL 2.49mL 1.25mL | 24.92mL 4.98mL 2.49mL | |
| CAS号 | 17328-16-4 | 
| 分子式 | C16H14Cl2N2O4S | 
| 分子量 | 401.26 | 
| SMILES Code | O=S(C1=CC=C(NC(CCl)=O)C=C1)(C2=CC=C(NC(CCl)=O)C=C2)=O | 
| MDL No. | MFCD00028183 | 
| 别名 | NSC 30176 | 
| 运输 | 蓝冰 | 
| InChI Key | SHRCVZJKZJGIHQ-UHFFFAOYSA-N | 
| Pubchem ID | 87052 | 
| 存储条件 | In solvent -20°C: 3-6个月 -80°C: 12个月 Pure form Sealed in dry,2-8°C | 
| 溶解方案 | DMSO: 120 mg/mL(299.05 mM),配合低频超声助溶,注意:DMSO长时间开封后,会吸水并导致溶解能力下降,请避免使用长期开封的DMSO 以下溶解方案都请先按照体外实验的方式配制澄清的储备液,再依次添加助溶剂: ——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议现用现配,当天使用; 以下溶剂前显示的百分比是指该溶剂在终溶液中的体积占比;如在配制过程中出现沉淀、析出现象,可以通过加热和/或超声的方式助溶 
 
 
 | 
 沪公网安备 31011702889066号
			
			沪ICP备2024050318号-1
			沪公网安备 31011702889066号
			
			沪ICP备2024050318号-1